Literature DB >> 8864446

Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma.

J D Nosanchuk1, K A Sepkowitz, R N Pearse, M H White, S D Nimer, D Armstrong.   

Abstract

We aimed to characterize the infectious complications of autologous bone marrow (AuBMT) and peripheral stem cell transplantation (PSCT) in patients with refractory leukemia and lymphoma. We performed a retrospective analysis of all patients (n = 56) with refractory leukemia or lymphoma treated with AuBMT or PSCT at Memorial Sloan-Kettering Cancer Center from January 1993 to July 1994. Records were available in 55, of whom 33 (60%) received AuBMT and 22 (40%) PSCT. Fifteen (27%) developed complicated infections, including 13 (39%) treated with AuBMT and two (9%) with PSCT. Complicated infections were caused by bacterial (11 episodes), fungal (four episodes), and viral (four episodes) pathogens. Five (9%) infections were fatal. In a multivariate model, only duration of neutropenia was significantly associated with development of complicated infection (P = 0.006). Thus, 27% of patients with refractory leukemia or lymphoma treated with AuBMT or PSCT developed complicated infections and 9% died of infection. Prolonged neutropenia was significantly associated with development of infection. Patients receiving PSCT had significantly lower rates of complicated infection, presumably due to the associated shorter duration of neutropenia. Future studies are needed to define the role of PSCT as treatment for refractory neoplastic disease.

Entities:  

Mesh:

Year:  1996        PMID: 8864446

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis.

Authors:  E Eleutherakis-Papaiakovou; M-A Dimopoulos; E Kastritis; D Christoulas; M Roussou; M Migkou; M Gavriatopoulou; D Fotiou; I Panagiotidis; D C Ziogas; N Kanellias; C Papadimitriou; E Terpos
Journal:  Bone Marrow Transplant       Date:  2017-08-14       Impact factor: 5.483

3.  The role of prophylactic antimicrobials during autologous stem cell transplantation: a single-center experience.

Authors:  B S Sohn; D H Yoon; S Kim; K Lee; E H Kang; J S Park; D H Lee; S H Kim; J Huh; C Suh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-04       Impact factor: 3.267

4.  Osteogenic differentiation of human placenta-derived mesenchymal stem cells (PMSCs) on electrospun nanofiber meshes.

Authors:  Dongmei Zhang; Aiping Tong; Liangxue Zhou; Fang Fang; Gang Guo
Journal:  Cytotechnology       Date:  2012-04-15       Impact factor: 2.058

5.  Cytotoxic chemotherapy administered to two patients with partially refractory leukaemia while receiving intensive care treatment.

Authors:  K A Al-Anazi; S Jacobs
Journal:  Support Care Cancer       Date:  2004-10       Impact factor: 3.603

6.  Risk of neutropenic fever and early infectious complications after autologous peripheral blood stem cell transplantation for malignant diseases.

Authors:  Keiko Fujii; Masako Aoyama; Katsuji Shinagawa; Keitaro Matsuo; Katsuto Takenaka; Kazuma Ikeda; Kensuke Kojima; Fumihiko Ishimaru; Katsuyuki Kiura; Hiroshi Ueoka; Kenji Niiya; Mitsune Tanimoto; Mine Harada
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

7.  Escherichia coli: an important pathogen in patients with hematologic malignancies.

Authors:  Daniel Olson; Abraham T Yacoub; Anita D Gjini; Gelenis Domingo; John N Greene
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-11-01       Impact factor: 2.576

Review 8.  Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients.

Authors:  Georg Maschmeyer; Antje Haas; Oliver A Cornely
Journal:  Drugs       Date:  2007       Impact factor: 11.431

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.